Shu Taishen announced that the company's subsidiary Beijetai recently received an official letter from the US FDA agreeing to conduct clinical trials with STSP-0601 to treat bleeding in patients with hemophilia A or B with inhibitors. The drug was previously approved by the State Drug Administration to issue a “Drug Registration Certificate” in June 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.